Lowell B Anthony
Ohio State University Comprehensive Cancer Center LAO · Lousiana State University Health Sciences Center-NO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lowell B Anthony as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05724108 · Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsNational Cancer Institute (NCI) · active not recruiting · Metastatic Neuroendocrine Tumor · principal investigator
- Ph1NCT04750954 · Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI) · active not recruiting · Neuroendocrine Neoplasm · principal investigator
- Ph2NCT00590343 · Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine TumorsLouisiana State University Health Sciences Center in New Orleans · completed · Metastatic Neuroendocrine Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026Named on NCT05724108, NCT04750954
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:51 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.J Clin Oncol · 2017221 citationsRCR 9.2
- Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.Semin Nucl Med · 2002191 citationsRCR 5.5
- Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.Endocr Relat Cancer · 2018106 citationsRCR 5.5
- In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.Cancer J Sci Am · 199875 citationsRCR 2.9
- Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.Neuroendocrinology · 201532 citationsRCR 1.2
- Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.J Clin Oncol · 198628 citationsRCR 1.9
- Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.Clin Ther · 201819 citationsRCR 0.9
- Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.J Clin Oncol · 199817 citationsRCR 0.8
- Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.J Gastrointest Cancer · 20219 citationsRCR 0.7